Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Economic burden and healthcare resource utilization

7 evidence topics · 7 sources

Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status

“Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Medicare costs of bladder cancer care by phase of care
Phase of careAnnualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars)
Initial (first 12 months after diagnosis)“$25.4”View highlighted excerpt for this quote
Continuing“$6.1”View highlighted excerpt for this quote
End of life, cancer death“$92.2”View highlighted excerpt for this quote
End of life, non-cancer death“$21.8”View highlighted excerpt for this quote